Dyne Therapeutics secures $275 million in debt financing with Hercules Capital for therapeutic programs.

From GlobeNewswire: 2025-06-30 16:01:00

Dyne Therapeutics, Inc. secured a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. The funding will support the advancement of Dyne’s programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), potentially leading to U.S. Accelerated Approval submissions in 2026. The facility includes an initial term loan of $100 million with additional tranches tied to specific milestones. This strategic financing provides Dyne with the flexibility needed to reach critical clinical and regulatory goals, positioning the company for a potential U.S. launch in DMD by 2027.

Hercules Capital, a leader in customized debt financing for life sciences and technology companies, expressed confidence in Dyne’s leadership and pipeline. The loan facility consists of five tranches, including an initial term loan of $100 million, and additional tranches totaling up to $175 million tied to clinical, regulatory, and commercial milestones. This funding structure allows Dyne to access capital as needed while progressing through key inflection points in 2025 and 2026, ultimately aiming for a potential U.S. launch in 2027.

Dyne Therapeutics focuses on developing therapeutics for genetically driven neuromuscular diseases, with clinical programs for DM1 and DMD, and preclinical programs for FSHD and Pompe disease. The company’s mission is to deliver functional improvement for individuals living with these diseases. Hercules Capital, Inc. is a specialty finance company providing senior secured venture growth loans to high-growth technology and life sciences companies. The partnership between Dyne and Hercules reflects a shared commitment to addressing critical unmet needs in the neuromuscular disease space.



Read more at GlobeNewswire: Dyne Therapeutics Secures Up to $275 Million in Debt